Your browser doesn't support javascript.
loading
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew, Yvette; Kim, Jae-Weon; Penson, Richard T; O'Malley, David M; Parkinson, Christine; Roxburgh, Patricia; Plummer, Ruth; Im, Seock-Ah; Imbimbo, Martina; Ferguson, Michelle; Rosengarten, Ora; Steeghs, Neeltje; Kim, Min Hwan; Gal-Yam, Einav; Tsoref, Daliah; Kim, Jae-Hoon; You, Benoit; De Jonge, Maja; Lalisang, Roy; Gort, Eelke; Bastian, Sara; Meyer, Kassondra; Feeney, Laura; Baker, Nigel; Ah-See, Mei-Lin; Domchek, Susan M; Banerjee, Susana.
Afiliación
  • Drew Y; Department of Medical Oncology, BC Cancer - Vancouver and University of British Columbia, Vancouver, British Columbia, Canada.
  • Kim JW; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Penson RT; Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • O'Malley DM; Division of Gynecology Oncology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
  • Parkinson C; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Roxburgh P; Medical Oncology, Beatson West of Scotland Cancer Centre, and School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Plummer R; Translational and Clinical Research Institute, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Imbimbo M; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
  • Ferguson M; Department of Oncology, NHS Tayside, Ninewells Hospital, Dundee, United Kingdom.
  • Rosengarten O; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Steeghs N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Kim MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Gal-Yam E; Chaim Sheba Medical Center, Tel HaShomer, Israel.
  • Tsoref D; Rabin Medical Center-Beilinson Campus, Petach Tikva and Tel-Aviv University, Tel-Aviv, Israel.
  • Kim JH; Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • You B; Service d'Oncologie Médicale, CITOHL, EPSLYON, Institut de Cancérologie des Hospices Civils de Lyon, IC-HCL, Université Claude Bernard Lyon 1, Lyon, France.
  • De Jonge M; Department of Medical Oncology, Erasmus Medisch Centrum, Rotterdam, the Netherlands.
  • Lalisang R; Division of Medical Oncology, Department of Internal Medicine, GROW - School of Oncology and Reproduction, Maastricht UMC+ Comprehensive Cancer Center, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Gort E; Department of Medical Oncology, UMC Utrecht, Utrecht, the Netherlands.
  • Bastian S; Medical Oncology and Haematology, Kantonsspital Graubuenden, Chur, Switzerland.
  • Meyer K; Late Development Oncology, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.
  • Feeney L; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Baker N; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.
  • Ah-See ML; Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Banerjee S; Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.
Clin Cancer Res ; 30(1): 50-62, 2024 01 05.
Article en En | MEDLINE | ID: mdl-37939124
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos